Development of a Conceptual Framework for Tuberculosis Management and Control; an Evidence Synthesis using Text Mining Software: A Review
,
Abstract
Background: The use of electronic systems supported by text-mining software applications that support the End TB strategy’ needs to be explored. This study aimed to address this knowledge gap, and synthesis of evidence.
Methods: The PubMed database was searched for structured review articles published in English since 2012 on interventions to control and manage TB. Nine hundred twenty-five articles met the inclusion criteria. The included articles were synthesized using the text and content analysis software Leximancer. The themes were chosen based on the hit words that emerged in the frequency and heat maps. After the themes were chosen, the concept built the themes based on likelihood.
Results: The framework resulting in the study focuses on early detection and treatment to minimize the chance of TB transmission in the population, especially for highly susceptable populations. The main area highlighted is the appropriate screening and treatment domains. The framework generated in this study is somewhat in line with the WHO Final TB Strategy. This study highlights the importance of improving TB prevention through a patient-centered approach and protecting susceptible populations.
Conclusion: Our findings will be helpful in guiding TB practice, policy development and future research. Future research can elaborate the framework and elicit feedback from TB management stakeholdesr to assess its utility.
1. World Health Organization. (2020). Tuber-culosis. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis
2. Lange C, Abubakar I, Alffenaar JWC, et al (2014). Management of patients with multidrugresistant/extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement. Eur Respir J, 44(1):23–63.
3. World Health Organisation (2021). Consol-idated Guidelines on Tuberculosis Treatment, Module 2: Systematic Screen-ing for Tuberculosis Disease. World Health Organisation - Geneva, pp:11-35
4. World Health Organisation (2013). End TB Strategy. World Health Origanisation, pp:53. Available from: https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy
5. Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al (2010). Tuberculosis control and elimi-nation 2010-50: cure, care, and social de-velopment. Lancet, 375 (9728): 1814–29.
6. World Health Organisation (2020). WHO Guidelines on Tuberculosis Infection Prevention and Control. World Health Organisation – Geneva, pp: 885–889. Available from: https://www.who.int/publications/i/item/9789240055889
7. Mohidem NA, Hashim Z, Osman M, Mu-haram FM, Elias SM, Shaharudin R (2020). Environment as the risk factor for tuberculosis in Malaysia: A systemat-ic review of the literature. Rev Environ Health, 36 (4): 493–9.
8. Pareek M, Greenaway C, Noori T, Munoz J, Zenner D (2016). The impact of migra-tion on tuberculosis epidemiology and control in high-income countries: a re-view. BMC Med,14:48.
9. Collins, David; Hafids, Firdaus; Su-raratdecha C (2017). The Economic Burden of TB in Indonesia. Int J Tuber and Lung Dis, 21(9): 1041-1048.
10. Vega V, Rodríguez S, van der Stuyft P, Seas C, Otero L (2021). Recurrent TB: a sys-tematic review and meta-analysis of the incidence rates and the proportions of relapses and reinfections. Thorax, 76 (5) :494–502.
11. Hasibuan ZA (2020). Towards Using Uni-versal Big Data in Artificial Intelligence Research and Development to Gain Meaningful Insights and Automation Systems. 2020 International Workshop on Big Data and Information Security (IWBIS), pp: 9–18.
12. Nunez-mir GC, Iii BVI, Pijanowski BC, Kong N (2016). Automated content analysis : Addressing the big literature challenge in ecology and evolution. Methods in Ecology and Evolution, 7 (11): 1262-1272.
13. Rahmah A, Santoso HB, Hasibuan ZA (2020). Conceptualizing Technology-Enhanced Learning Constructs: A Jour-ney of Seeking Knowledge Using Litera-ture-Based Discovery. Advances in Intelli-gent Systems and Computing, 1228:746–59.
14. Doan TN, Varleva T, Zamfirova M, Tyufekchieva M, Keshelava A, Hristov K, et al (2019). Strategic investment in tuberculosis control in the Republic of Bulgaria. Epidemiol Infect, 147:e304.
15. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al (2015). WHO’s new end TB strategy. Lancet, 385(9979):1799–1801.
16. Nuermberger E, Bishai WR, Grosset JH (2004). Latent tuberculosis infection. Semin Respir Crit Care Med, 25(3):317–36.
17. Weld ED, Dooley KE (2018). State-of-the-Art Review of HIV-TB Coinfection in Special Populations. Clin Pharmacol Ther, 104 (6): 1098–1109.
18. Mil C, Peir JS (2014). Screening for active tuberculosis in high-risk groups. Int J Tu-berc Lung Dis, 18 (12): 1459–65.
19. Alexander M, Gupta A, Mathad JS (2019). Is there a connection between gestational diabetes mellitus, human immunodefi-ciency virus infection, and tuberculosis? Int J Tuberc Lung Dis, 23 (1): 19–25.
20. Prasad R, Singh A, Gupta N (2019). Adverse drug reactions in tuberculosis and man-agement. Indian J Tuberc, 66(4):520–32.
21. Aderita NI, Murti B, Suryani N (2017). Risk Factors Affecting Multi-Drug Resistant Tuberculosis in Surakarta and Wonogiri, Central Java, Indonesia. Journal of Epide-miology and Public Health, 1 (2): 86–99.
22. World Health Organisation (2012). A prac-tical handbook on the pharmacovigi-lance of medicines used in the treat-ment of tuberculosis. World Health Or-ganization-Geneva,pp: 111.
23. Girum T, Muktar E, Lentiro K, Wondiye H, Shewangizaw M (2018). Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: A systematic review and meta-analysis of the prevalence, de-terminants and treatment outcome. Trop Dis Travel Med Vaccines, 4:5.
24. Li B ying, Shi W pei, Zhou C ming, Zhao Q, Diwan VK, Zheng X bin, et al (2020). Rising challenge of multidrug-resistant tuberculosis in China : a predictive study using Markov modeling. Infect Dis Poverty, 9 (1):65.
25. World Bank (2019). Tuberculosis treatment success rate (% of new cases) – Malaysia World Development Indicators. Availa-ble from: https://data.worldbank.org/indicator/SH.TBS.CURE.ZS?locations=ID
26. Soeroto AY, Nurhayati RD, Purwiga A, Les-tari BW, Pratiwi C, Santoso P, et al (2022). Factors associated with treatment outcome of MDR/RR-TB patients treat-ed with shorter injectable based regi-men in West Java Indonesia. PLoS One, 17 (1): e0263304.
27. The Ministry of Health the Republic of In-donesia(2020). The Republic of Indone-sia Joint External Monitoring Mission for Tuberculosis. The Ministry of Health the Republic of Indonesia- Jakarta, pp: 63-90.
28. Ragonnet R, Trauer JM, Denholm JT, Ma-rais BJ, McBryde ES (2017). High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: Where do they come from?. BMC Infect Dis, 17 (1): 36.
29. Wedari NLPH, Pranata IWA, Budayanti NNS, Sukrama I dewa M (2021). Tuber-culosis cases comparison in developed country ( Australia ) and developing country ( Indonesia ): a comprehensive review from clinical , epidemiological , and microbiological aspects. Intisari Sains Medis, 12 (2): 421–6.
30. World Health Origanisation (2018). Global Tuberculosis Report. World Health Or-ganization- Geneva, p:59. Available from: https://www.who.int/publications/i/item/9789241565646
31. World Health Organization (2016). The End TB Strategy: Global strategy and targets for tuberculosis, prevention, care and control after 2015. World Health Organization- Geneva. Available from: https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19
32. Marguari D, Basri C, Indrasari W, Sebayang M (2020). Social Barriers to Accessing Quality TB Service: Key population, Le-gal Environment and Gender Assess-ment. Stop TB Partnership. https://stoptb.org/assets/documents/communi-ties/CRG/TB%20CRG%20Assessment%20Indonesia.pdf
33. Surya A, Setyaningsih B, Suryani Nasution H, Gita Parwati C, Yuzwar YE, Osberg M, et al (2017). Quality Tuberculosis Care in Indonesia: Using Patient Path-way Analysis to Optimize Public-Private Collaboration. J Infect Dis, 216 (suppl-7): S724–32.
34. Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, de Vries G, Diel R, et al (2015). Towards tuberculosis elimination: An action framework for low-incidence countries. Eur Respir J, 45 (4): 928–52.
35. Narasimhan P, Wood J, MacIntyre CR, Mathai D (2013). Risk factors for tuber-culosis. Pulm Med, 2013: 828939.
2. Lange C, Abubakar I, Alffenaar JWC, et al (2014). Management of patients with multidrugresistant/extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement. Eur Respir J, 44(1):23–63.
3. World Health Organisation (2021). Consol-idated Guidelines on Tuberculosis Treatment, Module 2: Systematic Screen-ing for Tuberculosis Disease. World Health Organisation - Geneva, pp:11-35
4. World Health Organisation (2013). End TB Strategy. World Health Origanisation, pp:53. Available from: https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy
5. Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al (2010). Tuberculosis control and elimi-nation 2010-50: cure, care, and social de-velopment. Lancet, 375 (9728): 1814–29.
6. World Health Organisation (2020). WHO Guidelines on Tuberculosis Infection Prevention and Control. World Health Organisation – Geneva, pp: 885–889. Available from: https://www.who.int/publications/i/item/9789240055889
7. Mohidem NA, Hashim Z, Osman M, Mu-haram FM, Elias SM, Shaharudin R (2020). Environment as the risk factor for tuberculosis in Malaysia: A systemat-ic review of the literature. Rev Environ Health, 36 (4): 493–9.
8. Pareek M, Greenaway C, Noori T, Munoz J, Zenner D (2016). The impact of migra-tion on tuberculosis epidemiology and control in high-income countries: a re-view. BMC Med,14:48.
9. Collins, David; Hafids, Firdaus; Su-raratdecha C (2017). The Economic Burden of TB in Indonesia. Int J Tuber and Lung Dis, 21(9): 1041-1048.
10. Vega V, Rodríguez S, van der Stuyft P, Seas C, Otero L (2021). Recurrent TB: a sys-tematic review and meta-analysis of the incidence rates and the proportions of relapses and reinfections. Thorax, 76 (5) :494–502.
11. Hasibuan ZA (2020). Towards Using Uni-versal Big Data in Artificial Intelligence Research and Development to Gain Meaningful Insights and Automation Systems. 2020 International Workshop on Big Data and Information Security (IWBIS), pp: 9–18.
12. Nunez-mir GC, Iii BVI, Pijanowski BC, Kong N (2016). Automated content analysis : Addressing the big literature challenge in ecology and evolution. Methods in Ecology and Evolution, 7 (11): 1262-1272.
13. Rahmah A, Santoso HB, Hasibuan ZA (2020). Conceptualizing Technology-Enhanced Learning Constructs: A Jour-ney of Seeking Knowledge Using Litera-ture-Based Discovery. Advances in Intelli-gent Systems and Computing, 1228:746–59.
14. Doan TN, Varleva T, Zamfirova M, Tyufekchieva M, Keshelava A, Hristov K, et al (2019). Strategic investment in tuberculosis control in the Republic of Bulgaria. Epidemiol Infect, 147:e304.
15. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al (2015). WHO’s new end TB strategy. Lancet, 385(9979):1799–1801.
16. Nuermberger E, Bishai WR, Grosset JH (2004). Latent tuberculosis infection. Semin Respir Crit Care Med, 25(3):317–36.
17. Weld ED, Dooley KE (2018). State-of-the-Art Review of HIV-TB Coinfection in Special Populations. Clin Pharmacol Ther, 104 (6): 1098–1109.
18. Mil C, Peir JS (2014). Screening for active tuberculosis in high-risk groups. Int J Tu-berc Lung Dis, 18 (12): 1459–65.
19. Alexander M, Gupta A, Mathad JS (2019). Is there a connection between gestational diabetes mellitus, human immunodefi-ciency virus infection, and tuberculosis? Int J Tuberc Lung Dis, 23 (1): 19–25.
20. Prasad R, Singh A, Gupta N (2019). Adverse drug reactions in tuberculosis and man-agement. Indian J Tuberc, 66(4):520–32.
21. Aderita NI, Murti B, Suryani N (2017). Risk Factors Affecting Multi-Drug Resistant Tuberculosis in Surakarta and Wonogiri, Central Java, Indonesia. Journal of Epide-miology and Public Health, 1 (2): 86–99.
22. World Health Organisation (2012). A prac-tical handbook on the pharmacovigi-lance of medicines used in the treat-ment of tuberculosis. World Health Or-ganization-Geneva,pp: 111.
23. Girum T, Muktar E, Lentiro K, Wondiye H, Shewangizaw M (2018). Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: A systematic review and meta-analysis of the prevalence, de-terminants and treatment outcome. Trop Dis Travel Med Vaccines, 4:5.
24. Li B ying, Shi W pei, Zhou C ming, Zhao Q, Diwan VK, Zheng X bin, et al (2020). Rising challenge of multidrug-resistant tuberculosis in China : a predictive study using Markov modeling. Infect Dis Poverty, 9 (1):65.
25. World Bank (2019). Tuberculosis treatment success rate (% of new cases) – Malaysia World Development Indicators. Availa-ble from: https://data.worldbank.org/indicator/SH.TBS.CURE.ZS?locations=ID
26. Soeroto AY, Nurhayati RD, Purwiga A, Les-tari BW, Pratiwi C, Santoso P, et al (2022). Factors associated with treatment outcome of MDR/RR-TB patients treat-ed with shorter injectable based regi-men in West Java Indonesia. PLoS One, 17 (1): e0263304.
27. The Ministry of Health the Republic of In-donesia(2020). The Republic of Indone-sia Joint External Monitoring Mission for Tuberculosis. The Ministry of Health the Republic of Indonesia- Jakarta, pp: 63-90.
28. Ragonnet R, Trauer JM, Denholm JT, Ma-rais BJ, McBryde ES (2017). High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: Where do they come from?. BMC Infect Dis, 17 (1): 36.
29. Wedari NLPH, Pranata IWA, Budayanti NNS, Sukrama I dewa M (2021). Tuber-culosis cases comparison in developed country ( Australia ) and developing country ( Indonesia ): a comprehensive review from clinical , epidemiological , and microbiological aspects. Intisari Sains Medis, 12 (2): 421–6.
30. World Health Origanisation (2018). Global Tuberculosis Report. World Health Or-ganization- Geneva, p:59. Available from: https://www.who.int/publications/i/item/9789241565646
31. World Health Organization (2016). The End TB Strategy: Global strategy and targets for tuberculosis, prevention, care and control after 2015. World Health Organization- Geneva. Available from: https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19
32. Marguari D, Basri C, Indrasari W, Sebayang M (2020). Social Barriers to Accessing Quality TB Service: Key population, Le-gal Environment and Gender Assess-ment. Stop TB Partnership. https://stoptb.org/assets/documents/communi-ties/CRG/TB%20CRG%20Assessment%20Indonesia.pdf
33. Surya A, Setyaningsih B, Suryani Nasution H, Gita Parwati C, Yuzwar YE, Osberg M, et al (2017). Quality Tuberculosis Care in Indonesia: Using Patient Path-way Analysis to Optimize Public-Private Collaboration. J Infect Dis, 216 (suppl-7): S724–32.
34. Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, de Vries G, Diel R, et al (2015). Towards tuberculosis elimination: An action framework for low-incidence countries. Eur Respir J, 45 (4): 928–52.
35. Narasimhan P, Wood J, MacIntyre CR, Mathai D (2013). Risk factors for tuber-culosis. Pulm Med, 2013: 828939.
| Files | ||
| Issue | Vol 52 No 12 (2023) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v52i12.14312 | |
| Keywords | ||
| Tuberculosis Automatic knowledge Framework Control Management | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Handayani S, Hinchcliff R, Hasibuan Z. Development of a Conceptual Framework for Tuberculosis Management and Control; an Evidence Synthesis using Text Mining Software: A Review. Iran J Public Health. 2023;52(12):2506-2515.
